Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NC-ND 4.0Cellular and Molecular Gastroenterology and Hepatology

Metabolic Dysfunction-Associated Steatohepatitis: Is There Evidence for Fractured CD4+ T-Cell Tolerance in the Immunopathogenesis

  • Abigail E. Russi1,2,3
  • Brian J. DeBosch1,2,3,4,5
5 affiliations
  1. 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana
  2. 2Riley Children's Health, Indianapolis, Indiana
  3. 3Nutrition and Molecular Metabolism Center, Indiana University School of Medicine, Indianapolis, Indiana
  4. 4Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana
  5. 5Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana
Read full textPDFDOICite

Abstract

Metabolic dysfunction–associated liver disease is defined by hepatic steatosis with concomitant metabolic risk factors and is the leading cause of chronic liver disease. In approximately one-third of individuals, the disease progresses to metabolic dysfunction–associated steatohepatitis, a more severe form encompassing steatosis with inflammation and hepatocellular injury predisposing to liver failure, cirrhosis, and hepatocellular carcinoma. The mechanism(s) responsible for this aberrant inflammation are unknown. In this review, we explore the breakdown of the hepatic tolerogenic environment in metabolic dysfunction–associated steatohepatitis with discussion on fractured CD4+ T cell tolerance as an integral driver of the progression of metabolic dysfunction–associated liver disease to metabolic dysfunction–associated steatohepatitis.

Related

  1. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
    Mohammed Alfawaz, Dareen Bajamaan, Lama Alghamdi +7
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
    Yuchen Fang, Lianjun Xing
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefPMC
  3. GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials
    Shi-ping Sun, Yan Fang, Li Liu +2
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Successive and Isoform-Specific Remodeling of Hepatic Drug-Metabolizing Enzymes during Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Progression
    Yusuke Ando, Takumi Arai, Yuki Tsukui +4
    Biological and Pharmaceutical BulletinPeer-reviewedCC BY-NCFull textPharmacology & toxicologyJ-STAGE
  5. Macrophage interferon regulatory factor 7 aggravates the progression of metabolic dysfunction-associated steatohepatitis.
    Xuhao Ni, Qingfa Bu, Yuan Liang +5
    Molecular biomedicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{russi2026metabolic,
  title = {{Metabolic Dysfunction-Associated Steatohepatitis: Is There Evidence for Fractured CD4+ T-Cell Tolerance in the Immunopathogenesis}},
  author = {Abigail E. Russi and Brian J. DeBosch},
  journal = {Cellular and Molecular Gastroenterology and Hepatology},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jcmgh.2026.101899},
  url = {https://doi.org/10.1016/j.jcmgh.2026.101899},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Metabolic Dysfunction-Associated Steatohepatitis: Is There Evidence for Fractured CD4+ T-Cell Tolerance in the Immunopathogenesis
AU  - Abigail E. Russi
AU  - Brian J. DeBosch
PY  - 2026
DA  - 2026/09/19
JO  - Cellular and Molecular Gastroenterology and Hepatology
DO  - 10.1016/j.jcmgh.2026.101899
UR  - https://doi.org/10.1016/j.jcmgh.2026.101899
AB  - Metabolic dysfunction–associated liver disease is defined by hepatic steatosis with concomitant metabolic risk factors and is the leading cause of chronic liver disease. In approximately one-third of individuals, the disease progresses to metabolic dysfunction–associated steatohepatitis, a more severe form encompassing steatosis with inflammation and hepatocellular injury predisposing to liver failure, cirrhosis, and hepatocellular carcinoma. The mechanism(s) responsible for this aberrant inflammation are unknown. In this review, we explore the breakdown of the hepatic tolerogenic environment in metabolic dysfunction–associated steatohepatitis with discussion on fractured CD4+ T cell tolerance as an integral driver of the progression of metabolic dysfunction–associated liver disease to metabolic dysfunction–associated steatohepatitis.
SN  - 2352-345X
ER  -